News Column

Reports Summarize Clinical Trials and Studies Findings from University of California (Bioengineering tools to elucidate and control the fate of...

June 30, 2014



Reports Summarize Clinical Trials and Studies Findings from University of California (Bioengineering tools to elucidate and control the fate of transplanted stem cells)

By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Clinical Research is the subject of a report. According to news reporting out of Irvine, California, by NewsRx editors, research stated, "For the last decade, stem cell therapies have demonstrated enormous potential for solving some of the most tragic illnesses, diseases and tissue defects worldwide. Currently, more than 1300 clinical trials use stem cell therapy to solve a spectrum of cardiovascular, neurodegenerative and autoimnnune diseases (http://www.clinicaltrials.gov, Jan 2014, search term: stem cell therapy; only currently recruiting and completed studies are included in the search)."

Our news journalists obtained a quote from the research from the University of California, "However, the efficacy of stem cell transplantation in patients has not been well established, and recent clinical trials have produced mixed results. We attribute this lack of efficacy in part to an incomplete understanding of the fate of stem cells following transplantation and the lack of control over cell fate, especially cell-homing and therapeutic functions. In the present review, we present two of our recently developed technologies that aim to address the above-mentioned bottlenecks in stem cell therapy specifically in the areas of MSCs (mesenchymal stem cells): (i) aptamer-based cell-surface sensors to study cellular microenvironments, and (ii) mRNA engineering technology to enhance the homing and immunomodulatory efficacy of transplanted stem cells. The first engineering strategy aims to elucidate the basic cellular signalling that occurs in the microenvironment of transplanted stem cells in real time. The second technique involves a simple mRNA transfection that improves the homing and anti-inflammatory capability of MSCs."

According to the news editors, the research concluded: "Although we have specifically applied these engineering techniques to MSCs, these strategies can be incorporated for almost any cell type to determine and control the fate of transplanted stem cells."

For more information on this research see: Bioengineering tools to elucidate and control the fate of transplanted stem cells. Biochemical Society Transactions, 2014;42():679-687. Biochemical Society Transactions can be contacted at: Portland Press Ltd, Third Floor, Eagle House, 16 Procter Street, London WC1V 6 Nx, England (see also Clinical Research).

Our news journalists report that additional information may be obtained by contacting R. Sridharan, University of California, Edwards Lifesci Center Adv Cardiovasc Technol, Irvine, CA 92697, United States. Additional authors for this research include J.M. Karp and W.A. Zhao.

Keywords for this news article include: Biotechnology, Irvine, California, Cell Therapy, United States, Bioengineering, Clinical Research, Biological Therapy, Stem Cell Research, North and Central America, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters